Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Multicenter, Double-Blind, Randomized, Placebo-Controlled Dose Titration Study to Evaluate the Safety, Tolerability and Pharmacodynamic Effects of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS).

Next Previous
Search
Trial Profile

A Phase II, Multicenter, Double-Blind, Randomized, Placebo-Controlled Dose Titration Study to Evaluate the Safety, Tolerability and Pharmacodynamic Effects of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS).

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 02 May 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tirasemtiv (Primary) ; Riluzole
  • Indications Amyotrophic lateral sclerosis
  • Focus Adverse reactions
  • Sponsors Cytokinetics

    • Most Recent Events

    • 22 Aug 2013 Pooled results of trials CY4024 and CY4025 published in Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, according to a Cytokinetics media release.
    • 17 Dec 2012 Results were presented at the 23rd International Symposium on ALS/MND, according to a Cytokinetics media release.
    • 29 Oct 2012 Primary endpoint of "Safety" has been met, according to results published in a Cytokinetics media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top